Newgenivf Group Limited (NIVF) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2023 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Newgenivf Group Limited  (NASDAQ: NIVF)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare


Newgenivf Group Limited's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Newgenivf Group Limited's ROA in the fourth quarter of 2025?
Newgenivf Group Limited achieved a return on average assets (ROA) of 29.65 % in its fourth quarter of 2025, this is above NIVF's average return on assets of 8.24%.
Newgenivf Group Limited assets over the 12 months ending in its fourth quarter of 2025 are valued at $33 million

ROA has improved compared to 0.42% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 39 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 157.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Total Assets Change 561.66 % 514.33 % 1904.52 % 1886.31 % 200.78 %
Y / Y Net Income Change 8873.35 % - - - -
Net Income (TTM) in million 10 0 0 0 0
Return On Assets (TTM) 29.65 % 0.42 % 0.57 % 0.97 % 3.19 %
NIVF's Total Ranking # 157 # # # # 3984
Total Assets (TTM) in million 33 33 33 33 5
Seq. Total Assets Change 0.19 % -0.91 % 0.92 % 560.4 % -6.98 %
Seq. Net Income Change - - - - -

NIVF's 5 Years Annual ROA >> Back to NIVF Management Effectiveness >> Compare NIVF ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 0
Sector # 40
Overall # 153

Return On Assets Statistics
High Average Low
29.73 %
8.24 %
-13.25 %
(Dec 31 2025)   (Dec 31 2024)



  News about Newgenivf Group Limited Return on Assets ROA

NewGen IVF Group Navigates Financial Clarifications and Major Technological Acquisition Amid Nasdaq Compliance Goals

In the rapidly evolving landscape of reproductive technology and healthcare, NewGen IVF Group Limited (NASDAQ: NIVF) stands at a pivotal juncture. The company finds itself clarifying its recent press release, issuing a critical statement regarding its compliance standing with Nasdaq while simultaneously announcing a significant acquisition set to enhance its service offerings.On February 20, 2025, NewGen IVF Group issued a press release

NewGenIvf Secures $100 Million Credit Line as It Tackles Nasdaq Compliance Hurdles and Expands Asian Fertility Ventures,

NewGenIvf Strengthens Financial Position with $100 Million Equity Line of Credit amid Nasdaq Compliance ChallengeIn a significant development for NewGenIvf Group Limited (NASDAQ: NIVF), the company has entered into a binding term sheet with White Lion Capital, LLC, which outlines a $100 million equity line of credit with the potential for expansion up to $500 million. This move, announced on November 18, 2024, is aimed at propelling NewGenIvf’s innovative projects within the burgeoning fertility solutions sector, particularly in the Asian market. Financial Backbone for GrowthThis $100 million credit line, facilitated by White Lion Capital—known for investing in high-growth, early-stage public companies—will provide NewGenIvf with the necessary financial flexibility to execute its vision and drive growth in a fast-evolving fertility industry. This funding comes at a crucial time as NewGenIvf is poised to leverage emerging opportunities in assisted reproductive technologies (ART), which have seen increasing demand in various Asian countries.



Financial Statements
Newgenivf Group Limited's Assets $ 33 million NIVF's Balance sheet
Newgenivf Group Limited's Income $ 10 million Quarterly NIVF's Income Statement
NIVF's Income by Division See NIVF's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023
FY
FY
Y / Y Total Assets Change 561.66 % -6.98 % - - -
Total Assets in million 33 5 5 0 0
Y / Y Net Income Change - - - - -
Net Income in million 10 0 0 0 0
Annual Return On Assets 29.67 % -9.57 % 2.04 % - -

NIVF's 5 Years Annual ROA >> Back to NIVF Management Effectiveness >> Compare NIVF ROA to its Competitors



Comment on NIVF's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 29.67 % compared to prior year, due to annual net income growth of % to $9.73 million, while value of Newgenivf Group Limited's overall assets grew just by 561.66 % to $32.79 million, compared to $32.79 a year before.


More Return On Assets Ratios
NIVF's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NIVF's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NIVF's Competitors
Subscribers only: Roa for Newgenivf Group Limited's Suppliers
Subscribers only: Return On Assets for NIVF's Customers

You may also want to know
NIVF's Roi NIVF's Inventory Turnover Ratio NIVF's Growth Rates NIVF's Dividend Comparisons
NIVF's Profitability Ratios NIVF's Asset Turnover Ratio NIVF's Dividend Growth
NIVF's Roe NIVF's Valuation Ratios NIVF's Financial Strength Ratios NIVF's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Sanuwave Health Inc   65.98 %
Exelixis Inc   61.66 %
Entera Bio Ltd   61.28 %
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %

Date modified: 2026-09-02T16:46:04+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.